knowledge -WSS

knowledge

author：comprehensive 2025-10-02 14:03:14 - browse：19527

LONDON — AstraZeneca said Friday an experimental drug tamped down the progression of a certain type of breast cancer in a Phase 3 trial, a win for the company after the same drug produced underwhelming results in a lung cancer trial over the summer.

The drug, called datopotamab deruxtecan or Dato-DXd for short, succeeded on one of its primary endpoints of improving progression-free survival compared to chemotherapy in certain breast cancer patients who had previously been treated with other therapies.

AstraZeneca, which is developing Dato-DXd with partner Daiichi Sankyo, said that the data for the other primary endpoint of overall survival were not “mature” as of this interim analysis, but that there was a positive trend. The trial is continuing.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Why Titanic fascinates society, still drawing tours to the wreckage

WSS

How redistricting in 6 states could affect who controls Congress

Judge rejects Trump's request to move Stormy Daniels hush

Mass General totes up its waste in a move to tackle climate change

Jury awards Florida girl burned by McDonald's Chicken McNugget $800,000 in damages

Stanford president faces new allegations over 1999 paper

How corporate America is slashing DEI workers amid backlash to diversity programs

hotspot

knowledge

focus

Drug repurposing or repositioning? The language matters

FDA approves Leqembi, a milestone in Alzheimer’s treatment

Hepatitis C has a cure — but many Americans still lack access to it

With fresh data, a dynamic duo powers Eli Lilly to new heights

State Dept. review finds Biden bears some blame for Afghanistan failures

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

At least 13 dead in Texas as scorching temps continue

Hospitals struggle to profit from CAR

Activists slam private health insurers over coverage restrictions

Neutralizing antibodies against HIV shows promise in children

Wikipedia

Stanford president faces new allegations over 1999 paper

The PBM ad wars are taking over Washington, D.C.

Drinking water from half of US faucets contains PFAS: Study

UPS workers' union leader explains what's at stake as strike edges closer

Stanford president's case begs question: Who takes blame?

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

focus

entertainment

leisure time

focus